First vaccine to protect older people from RSV approved at EU level 

Once brought to market, Arexvy will be the first vaccine to immunise adults over the age of 60 against lower respiratory tract disease caused by RSV.

The European Medicines Agency (EMA) has recommended the EU marketing authorisation of the first vaccine to protect older adults from respiratory syncytial virus (RSV) infection.

A common respiratory virus that usually causes mild, cold-like symptoms, most people tend to recover from RSV within one to two weeks.